上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

601607 上海医药

已收盘 05-07 15:00:00

{"stockData":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":18.07,"timestamp":1715065200000,"preClose":18.09,"halted":0,"volume":11328150,"delay":0,"floatShares":1932000000,"shares":3703000000,"eps":1.0242,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.02,"latestTime":"05-07 15:00:00","open":18.08,"high":18.14,"low":17.84,"amount":204000000,"amplitude":0.0166,"askPrice":18.07,"askSize":550,"bidPrice":18.06,"bidSize":559,"shortable":0,"etf":0,"ttmEps":1.0242,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1715131800000},"adr":0,"adjPreClose":18.09,"symbolType":"stock","openAndCloseTimeList":[[1715045400000,1715052600000],[1715058000000,1715065200000]],"highLimit":19.9,"lowLimit":16.28,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":3703301054,"pbRate":0.96,"roa":"--","roe":"2.23%","epsLYR":1.02,"committee":-0.099214,"marketValue":66919000000,"floatMarketCap":34903000000,"peRate":17.643039,"changeRate":-0.0011,"turnoverRate":0.0059,"status":1},"requestUrl":"/m/hq/s/601607/","defaultTab":"news","newsList":[{"id":"2433624430","title":"上海医药05月07日遭主力抛售1537万元 环比增加194.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2433624430","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2433624430?lang=zh_cn&edition=full","pubTime":"2024-05-07 15:18","pubTimestamp":1715066283,"startTime":"0","endTime":"0","summary":"05月07日, 上海医药股价跌0.11%，报收18.07元，成交金额2.04亿元，换手率0.59%，振幅1.66%，量比0.93。上海医药今日主力资金净流出1537万元，上一交易日主力净流出522万元，今日环比增加194.44%。该股近5个交易日上涨1.46%，主力资金累计净流入1382万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1090万元，其中净流入天数为12日。净流出前三个股分别为上海医药、柳药集团、一心堂。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405071524228ae410cf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405071524228ae410cf&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433913446","title":"上海医药(02607.HK)左西孟旦注射液获批生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2433913446","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2433913446?lang=zh_cn&edition=full","pubTime":"2024-05-06 16:59","pubTimestamp":1714985940,"startTime":"0","endTime":"0","summary":"上海医药(02607.HK) 公布，其全资子公司上药东英的左西孟旦注射液收到国家药品监督管理局颁发的《药品注册证书》(证书编号：2024S00642)，此药品获批准生产。该药品主要适用于传统治疗疗效不佳，并且需要增加心肌收缩力的急性失代偿心力衰竭(ADHF)的短期治疗。(sl/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-05-06 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20210429113037512_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20210429113037512_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1347555&catg=4&source=AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2433446312","title":"上海医药(02607)：左西孟旦注射液获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2433446312","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2433446312?lang=zh_cn&edition=full","pubTime":"2024-05-06 16:57","pubTimestamp":1714985840,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)发布公告，近日，上海医药集团股份有限公司下属全资子公司上药东英(江苏)药业有限公司的左西孟旦注射液收到国家药品监督管理局颁发的《药品注册证书》(证书编号：2024S00642)，该药品获得批准生产。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1117566.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433448912","title":"上海医药(601607.SH)：左西孟旦注射液获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2433448912","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2433448912?lang=zh_cn&edition=full","pubTime":"2024-05-06 16:22","pubTimestamp":1714983761,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)公告，公司下属全资子公司上药东英(江苏)药业有限公司(简称“上药东英”)的左西孟旦注射液收到国家药品监督管理局(简称“国家药监局”)颁发的《药品注册证书》(证书编号：2024S00642)，该药品获得批准生产。据悉，左西孟旦注射液是钙增敏剂，以钙离子浓度依赖的方式与心肌肌钙蛋白 C 结合而产生正性肌力作用，增强心肌收缩力，同时可通过使 ATP 敏感的 K +通道 (KATP)开放舒张血管，舒张冠状动脉阻力血管和静脉容量血管，改善冠脉的血流供应，主要适用于传统治疗疗效不佳，并且需要增加心肌收缩力的急性失代偿心力衰竭(ADHF)的短期治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1117521.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432930446","title":"上海医药(02607.HK)：注射用帕瑞昔布钠新增规格获内地批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2432930446","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2432930446?lang=zh_cn&edition=full","pubTime":"2024-05-02 09:36","pubTimestamp":1714613760,"startTime":"0","endTime":"0","summary":"上海医药(02607.HK) 公布，下属全资子公司上药东英(江苏)药业的注射用帕瑞昔布钠收到国家药监局颁发的《药品补充申请批准通知书》，该药品新增规格40mg获得批准。注射用帕瑞昔布钠主要用于手术后疼痛的短期治疗，最早由辉瑞研发，于2002年在欧洲上市。(ha/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-30 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20210429113036647_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20210429113036647_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1346761/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2431031450","title":"上海医药最新公告：注射用帕瑞昔布钠新增规格获得批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2431031450","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431031450?lang=zh_cn&edition=full","pubTime":"2024-04-30 18:49","pubTimestamp":1714474161,"startTime":"0","endTime":"0","summary":"上海医药公告，公司基于对研发项目未来市场价值、业务协同以及后续开发投入等因素的综合评估，决定终止I010项目、B002项目以及B003项目三个研发项目的临床试验及后续开发。按照相关会计准则和公司会计政策，上述研发项目的研发投入已全部费用化并计入相应会计期间损益。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000045028.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431319035","title":"上海医药(02607)注射用帕瑞昔布钠新增规格40mg获得批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2431319035","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431319035?lang=zh_cn&edition=full","pubTime":"2024-04-30 18:47","pubTimestamp":1714474038,"startTime":"0","endTime":"0","summary":"2023年3月，上药东英就该药品新增40mg规格向国家药监局提出申请并获受理。IQVIA数据库显示，2023年注射用帕瑞昔布钠医院采购金额为人民币2.72亿元。公告称，本次取得药品补充申请批准通知书是在注射用帕瑞昔布钠20mg的基础上新增了40mg规格的产品，能进一步丰富患者的用药选择，有助于扩大该药品的市场份额，提升市场竞争力，将对公司经营产生积极的影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1116394.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431319499","title":"上海医药(601607.SH)：终止I010项目、B002项目以及B003项目三个研发项目的临床试验及后续开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2431319499","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2431319499?lang=zh_cn&edition=full","pubTime":"2024-04-30 18:34","pubTimestamp":1714473291,"startTime":"0","endTime":"0","summary":"格隆汇4月30日丨上海医药(601607.SH)公布，为合理配置研发资源、聚焦优势研发项目，公司基于对研发项目未来市场价值、业务协同以及后续开发投入等因素的综合评估，决定终止I010项目、B002项目以及B003项目三个研发项目的临床试验及后续开发。其中，I010项目及B002项目处于I期临床试验阶段，B003项目处于II期临床试验阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301834568b65e94a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301834568b65e94a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431758316","title":"上海医药最新公告：终止I010项目、B002项目及B003项目的临床试验及后续开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2431758316","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431758316?lang=zh_cn&edition=full","pubTime":"2024-04-30 18:30","pubTimestamp":1714473002,"startTime":"0","endTime":"0","summary":"上海医药公告，为合理配置研发资源、聚焦优势研发项目，公司基于对研发项目未来市场价值、业务协同以及后续开发投入等因素的综合评估，决定终止I010项目、B002项目以及B003项目三个研发项目的临床试验及后续开发。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000044013.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431316736","title":"上海医药(601607.SH)：注射用帕瑞昔布钠新增规格获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2431316736","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431316736?lang=zh_cn&edition=full","pubTime":"2024-04-30 18:29","pubTimestamp":1714472959,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)公告，近日，公司下属全资子公司上药东英(江苏)药业有限公司(“上药东英”)的注射用帕瑞昔布钠(“该药品”)收到国家药品监督管理局(“国家药监局”)颁发的《药品补充申请批准通知书》，该药品新增规格40mg获得批准。据悉，注射用帕瑞昔布钠主要用于手术后疼痛的短期治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1116369.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431874323","title":"国金证券：给予上海医药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2431874323","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431874323?lang=zh_cn&edition=full","pubTime":"2024-04-30 11:14","pubTimestamp":1714446850,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司近期对上海医药进行研究并发布了研究报告《创新药管线渐丰，中药增长，转型提速中》，本报告对上海医药给出买入评级，当前股价为18.04元。维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有6家机构给出评级，买入评级5家，增持评级1家；过去90天内机构目标均价为22.19。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000024171.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430084794","title":"上海医药获信达证券买入评级，商业创新业务表现亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2430084794","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430084794?lang=zh_cn&edition=full","pubTime":"2024-04-28 15:14","pubTimestamp":1714288464,"startTime":"0","endTime":"0","summary":"4月28日，上海医药获信达证券买入评级，近一个月上海医药获得2份研报关注。研报认为，2024Q1医药工业业务短期承压，医药商业业务持续稳健增长。公司商业创新业务表现亮眼，创新药板块销售同比增长约33%，并成功引入4个进口总代品种；药品CSO业务实现销售金额17亿元，同比增长约128%；进口疫苗终端推广团队持续扩充，目前疫苗推广团队已由2023年第一季度的340人增加至720余人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042815143087b9d47e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042815143087b9d47e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430799084","title":"信达证券发布上海医药研报，2024Q1医药商业营收增长8%，商业创新业务表现亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2430799084","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2430799084?lang=zh_cn&edition=full","pubTime":"2024-04-28 15:04","pubTimestamp":1714287864,"startTime":"0","endTime":"0","summary":"信达证券04月28日发布研报称，给予上海医药（601607.SH，最新价：17.85元）评级。评级理由主要包括：1）2024Q1医药工业业务短期承压，医药商业业务持续稳健增长；2）“自主研发+并购引进+孵化培育”驱动，2024Q1创新进展再创佳绩。风险提示：应收账款回收不及时，融资利率上行，市场竞争加剧，工业新品上市进度不及预期，集采降价超预期。AI点评：上海医药近一个月获得1份券商研报关注，买入1家。文章来源：每日经济新闻原标题：信达证券发布上海医药研报，2024Q1医药商业营收增长8%，商业创新业务表现亮眼","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404281516478b5cf8c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404281516478b5cf8c9&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430293781","title":"图解上海医药一季报：第一季度单季净利润同比增1.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430293781","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430293781?lang=zh_cn&edition=full","pubTime":"2024-04-27 02:01","pubTimestamp":1714154512,"startTime":"0","endTime":"0","summary":"证券之星消息，上海医药2024年一季报显示，公司主营收入701.53亿元，同比上升5.93%；归母净利润15.42亿元，同比上升1.62%；扣非净利润13.75亿元，同比上升1.3%；负债率62.25%，投资收益1.66亿元，财务费用3.74亿元，毛利率11.44%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042700003578.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430748472","title":"上海医药2024年一季报：业绩稳健增长 创新加速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2430748472","media":"中国财富通","top":-1,"share":"https://www.laohu8.com/m/news/2430748472?lang=zh_cn&edition=full","pubTime":"2024-04-26 20:56","pubTimestamp":1714136183,"startTime":"0","endTime":"0","summary":"4月27日，上海医药集团股份有限公司发布2024年一季报。报告期内，公司实现营业收入701.53亿元，同比增长5.93%，其中：医药工业实现销售收入69.44亿元；医药商业实现销售收入632.09亿元，同比增长8.19%。报告期内，公司研发投入7.15亿元，同比增加30.78%。报告期内，公司新增2项新药管线。报告期内，公司继续保持进口创新药总代的领先地位，创新药板块销售同比增幅约33%，成功引入4个进口总代品种。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=n4ZPWI6ZbJE%3D","is_publish_highlight":false,"gpt_icon":0},{"id":"2430922081","title":"上海医药最新公告：一季度净利润15.42亿元 同比增加1.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430922081","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430922081?lang=zh_cn&edition=full","pubTime":"2024-04-26 19:12","pubTimestamp":1714129921,"startTime":"0","endTime":"0","summary":"上海医药发布2024年一季度报告，报告期内公司实现营业收入701.53亿元，同比增加5.93%;归属于上市公司股东的净利润15.42亿元，同比增加1.62%;归属于上市公司股东的扣除非经常性损益的净利润13.75亿元，同比增加1.3%;基本每股收益0.42元。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600048040.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430224733","title":"上海医药(601607.SH)发布一季度业绩，净利润15.42亿元 同比增加1.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430224733","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430224733?lang=zh_cn&edition=full","pubTime":"2024-04-26 18:52","pubTimestamp":1714128732,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布2024年一季度报告，报告期内公司实现营业收入701.53亿元，同比增加5.93%;归属于上市公司股东的净利润15.42亿元，同比增加1.62%;归属于上市公司股东的扣除非经常性损益的净利润13.75亿元，同比增加1.3%;基本每股收益0.42元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1111957.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430522510","title":"上海医药最新公告：拟发行余额不超150亿元债务融资产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2430522510","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430522510?lang=zh_cn&edition=full","pubTime":"2024-04-26 17:47","pubTimestamp":1714124828,"startTime":"0","endTime":"0","summary":"上海医药公告，拟发行余额不超过等值人民币150亿元的各类短期债务融资产品和中长期债务融资产品。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600042119.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430240423","title":"上海医药(02607)拟申请发行各类短期债务融资产品和中长期债务融资产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2430240423","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430240423?lang=zh_cn&edition=full","pubTime":"2024-04-26 17:14","pubTimestamp":1714122850,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)发布公告，公司拟申请发行余额不超过等值人民币150亿元的各类短期债务融资产品和中长期债务融资产品，融资产品类别包括但不限于短期融资券、超短期融资券、短期公司债券、中期票据、中长期公司债券、永续债、类永续债、资产支持票据、绿色债务融资工具、科创票据和其他短期及中长期债务融资产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1111643.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1994-03-24","address":"上海市浦东新区中国(上海)自由贸易试验区张江路92号","stockEarnings":[{"period":"1week","weight":0.0017},{"period":"1month","weight":0.0409},{"period":"3month","weight":0.0302},{"period":"6month","weight":0},{"period":"1year","weight":-0.1904},{"period":"ytd","weight":0.0813}],"companyName":"上海医药集团股份有限公司","boardCode":"AI0052","perCapita":"23808股","boardName":"零售业","registeredCapital":"370330万元","compareEarnings":[{"period":"1week","weight":0.0089},{"period":"1month","weight":0.0233},{"period":"3month","weight":0.1259},{"period":"6month","weight":0.0289},{"period":"1year","weight":-0.0581},{"period":"ytd","weight":0.0557}],"survey":"　　上海医药集团股份有限公司主营业务为医药研发与制造、分销与零售。主要产品为丹参酮ⅡA磺酸钠注射液、注射用乌司他丁、硫酸羟氯喹片、注射用二丁酰环磷腺苷钙、注射用盐酸头孢替安、丹参片、参麦注射液、瓜蒌皮注射液、尪痹片、银杏酮酯等。集团在证券之星、第一财经以及上海市股份公司联合会共举办的\"上海上市公司评选\"中荣获\"最佳转型奖\"。中国医药上市公司竞争力50强榜首,中国医药行业\"十大最具影响力企业\"之一,\"投资者关系管理百强\";荣列上海企业100强第19位、上海制造业企业50强第9位、中国企业500强第203位、中国制造业企业500强第99位、中国制药工业百强第3位等。","serverTime":1715090399273,"listedPrice":4.5,"stockholders":"81129人(较上一季度增加Infinity%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,601607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}